reviewglomerulonephritischemokinsIL-8Witlebrandfactorplasminogen activatorfibronectinобзоргломерулонефритхемокиныинтерлейкин-8фактор Виллебрандаактиватор плазминогенафибронектин1.Segerer S., Nelson P. J., Schlondorff D. Chemokines, chemokine receptors and renal disease: from basic science to pathophysiologic and therapeutic studies. J. Am. Soc. Nephrol. 2000; 11: 152-176.2.Anders H. J., Vielhauer V., Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 2003; 63: 401-415.3.Wada Т., Yokoyama H., Kobayashi K. Chemokines: new target molecules in renal disease. Clin. Exp. Nephrol. 2000; 4: 273- 280.4.Козловская Л. В., Тареева И. Е., Мухин Н. А., Неверов Н. И. Мочевые тесты воспаления при гломерулонефрите. Тер. арх. 1994; 6: 11-15.5.Wada Т., Yokoyama H., Tomosugi N. et al. Detection of urinary interleukin-8 in glomerular diseases. Kidney Int. 1994; 46: 455-460.6.Yokoyama K, Wada T, Furuichi K. et al. Urinary levels chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J. Leukocyte Biol. 1998; 63: 493-499.7.Wada Т., Furuichi K, Segawa С et al. MlP-la and MCP-1 contribute crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int. 1999; 56: 995-1003.8.Grandaliano G., Gesualdo L., Ranieri G. et al. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: A pathogenic role in interstitial monocyte recruit-ment. J. Am. Soc. Nephrol. 1996; 7: 906-913.9.Zoja C, Donadelli R., Colleoni S. et al. Protein overload stimulates RANTES production by proxomal tubular cells depend ing on NF-kappaB activation. Kidney Int. 1998; 53: 1608- 1615.10.Guijarro C, Egido J. Transcription factor-kB (NF-kB) and renal disease. Kidney Int. 2001; 59: 415-424.11.Wada Т., Furuichi K, Sakai N. et al. A new anti-inflammatory compound FR 167653 ameliorates crescentic glomerulonephritis in KWY rats. J. Am. Soc. Nephrol. 2000; 11: 1534-1541.12.Wada Т., Tomosugi N.. Naito T. et al. Prevention of proteinuria by administration of anti-interleukin 8 antibody in experi- mental acute immune complex-induced glomerulonephritis. J. Exp. Med. 1994; 180: 1135-1140.13.Wada Т., Yokoyama H, Furuichi K. et al. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemo- -87 tactic and activating factor (MCAF/MCP-1). FASEB J. 1996; 10: 1418-1425.14.Chen S., Bacon К. В., Li L. et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenua- tion of glomerulonephritis in Wistar-Kyoto (WKY) rats byvMIP-II. J. Exp. Med. 1998; 188: 193-198.15.Kang D. H, Kanellis J., Hugo C. et al. Role of microvascular endothelium in progressive renal disease. J. Am. Soc. Neph- rol. 2002; 13: 806-816.16.Бобкова И. Н, Козловская Л. В., Полянцева Л. Р., ТарееваИ. Е. Клиническое значение определения фактора Виллебранда у больных волчаночным нефритом. Тер. арх. 1995; 5: 14-16.17.Козловская Л. В., Бобкова И. И., Щербак А. В., ПлиеваО. К. Клиническое значение определения в моче больных гломерулонефритом молекулярных медиаторов воспаления. Нефрология 2003; 7: 197-198.18.Бобкова И. Н., Полянцева Л. Р., Тареева И. Е. и др. Тест венозной окклюзии в оценке фибринолитической активности сосудистого эндотелия у больных волчаночным нефритом. Тер. арх. 1995; 4: 42-45.19.Rerolle J. P., Hertig A. et al. Plasminogen activator inhibitor I is a potential target in renal fibrogenesis. Kidney Int. 2000; 58: 1841-1850.20.Hamano K. et al. Expression of glomerular plasminogen activator inhibitor type I in glomerulonephritis. Am. J. Kidney Dis. 2002; 39 (4): 695-70521.Щербак А. В., Балкаров И. М., Козловская Л. В. и др. Снижение фибринолитической активности мочи у пациентов с наследственно обусловленным нарушением обмена мочевой кислоты. Тер. арх. 2001; 6: 8-10.22.Dennler H, Itoh S., Vivien D. et al. Direct binding of Smad 3 and Smad 4 to critical TGF-p-inducible elements in the promoter of human plasminogen activator inhibitor type-I gene.EMBO J. 1998; 17: 3091-3100.23.Sawa Y., Sobel B. E., Fum S. Inhibition of type-I plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscule cells. J. Biol. Chem. 1994; 269: 14149-14152.24.Ciemewski С S., Babinska A., Swiatkowska M. Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells.Eur. J. Biochem. 1995; 227: 494-499.25.Козловская Л. В., Бобкова И. Н., Варшавский В. А. и др. Фибронектин мочи как показатель процессов фиброзирования в почке при нефрите. Тер. арх. 1999; 6: 34-38.26.Plieva О. К, Shvetsov М., Kozlovskaya L. et al. Nephroprotective and antifibrogenic effects of angiotensin receptor blocker valsartan in chronic glomerulonephritis patients. Nephrol. Di- al. Transplant. 2003; 18: 134.27.Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 1998; 339: 1448-1456.28.Meyer T. Tubular injury in glomerular disease. Kidney Int. 2003; 63: 774-787.29.Vliet V., Isolde E., Anita I. et al. Fibronectin accumulation in glomerulosclerotic lesions: Self-assembly sites and the heparin II binding domain. Kidney Int. 2002; 61: 481-489.